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1. Introduction 
The aim of this article is to highlight the existence 
of a range of hormones which can exert rapid catabolic 
effects on the liver. Several of these hormones do not 
appear to act via cyclic-AMP, whereas cations may 
be implicated in the response mechanisms. For com- 
parison, facets of the more well-established actions of 
glucagon and adrenaline will be mentioned. An under- 
lying purpose is to consider the functional significance 
of hepatic metabolic processes in adaptive and patho- 
logical states, as only in this way can the importance 
of hormonal effects be judged. As a prelude to this 
and the other objectives, the preferred blood-borne 
precursors for hepatic biosynthesis will be reviewed. 
A disclaimer must be entered against the possibility 
of comprehensive coverage here of relevant published 
articles. There are too many excellent papers, to 
permit such coverage. Instead, a selective and some- 
what personalised approach is adopted. 
2. Glycogen and glycerides: formation and fate 
A major locus of short-term hormone action on the 
liver is on the metabolism of the main fuel stores in 
the tissue viz. glycogen and glycerides. We may reca- 
pitulate some common features in the metabolism 
and function of these molecules (scheme 1). Both 
can be rapidly synthesised de novo (‘neogenesis’) from 
simple metabolites in the carbohydrate/amino acid 
pool; thus in pathway terms, gluconeogenesis is to 
some extent analogous to fatty acid synthesis (‘lipo- 
neogenesis’). Also, conversion of glucose-phosphates 
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to glycogen is analogous to ‘esterification’ of fatty 
acyl esters to glycerides. Finally, both glycogen and 
glycerides can be degraded by pathways which 
supply acetyl units for combustion, support ATP 
turnover during conversion to acetyl units, and 
produce soluble partial degradation products (lactate 
plus pyruvate, and ketone bodies, respectively). 
Lactate and pyruvate are major precursors of both 
glycogen and glycerides in the liver, via neogenesis of 
glucose and fatty acids. Scheme 1 illustrates the 
prime role of pyruvate in the synthesis of these key 
storage molecules. An experimental basis for this view 
has come mainly from studies with the perfused liver. 
Thus in starved rats, synthesis of glycogen in response 
to ingested glucose does not involve blood-borne 
glucose as a carbon source, but rather a continuation 
of gluconeogenesis, hexose-phosphate products being 
directed to glycogen by the stimulatory role of glucose 
[l] . In perfused livers from fed animals, blood-borne 
glucose is also a good carbon-source for synthesised 
glycogen [2] ; this has also been shown in cell suspen- 
sions [3]. 
In perfused liver of fed mice [4], or rat hepatocyte 
suspensions [5] lactate is preferred to glucose as a 
precursor of synthesised fatty acids. The lack of a 
major role of blood-borne glucose in providing carbon 
for fatty acids synthesised in the liver has been con- 
firmed in intact mice [6] or rats (table II of ref. [7]). 
An overall implication of these observations is that 
the fate of blood-borne lactate in liver can involve 
rapid conversion to both glucose and fatty acid (as 
well as to carbon dioxide). The balance between these 
fates depends on the control of the initial reactions 
of intra-mitochondrial pyruvate, thus emphasising the 
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Scheme 1. Inter-relationships and similarities in liver between the metabolism of glucose and fatty acids. Some major pathways 
currently thought to operate in the metabolism of glucose and fatty acids in liver parenchymal cells are shown in a simplified 
scheme. Analogies between the synthesis de novo of glucose and fatty acids from pyruvate (or, e.g., lactate) are highlighted. 
Where the boxes (pools) are in the same horizontal position on the diagram, or have a similar shape, this indicates equivalence 
of metabolic function. Abbreviations: Glu, Glucose; Pyr, Pyruvate; Lac, Lactate; Cit, Citrate; Mal, Malate; OAA, Oxaloacetate; 
Asp, Aspartate; AcAc, Acetoacetate; 3-OH-but, 3-hydroxybutyrate; PA, fatty acids; CoA, coenzyme A; P, Phosphate. Neogenesis 
of glucose or fatty acids is highlighted by a thick line; otherwise there are no implications about the relative predominance of 
pathways, which will alter depending on the state of the animal. The broken line indicates the mitochondrial membrane. 
importance of the permease which carries pyruvate 
into mitochondria [8,9]. 
Turning to glycogen breakdown, this process has 
its major role in releasing glucose to blood, but can 
also supply acetyl units for fatty acid synthesis [4], 
presumably at times when there is net glycogen 
breakdown rather than synthesis. Indeed, this could 
constitute the main role of hepatic glycolysis [lo] 
(since blood-borne glucose does not significantly 
enter this ‘pathway’), although a role in providing 
acetyl units for oxidation to CO* also seems probable. 
The degradation of glycogen and glycerides, to 
glucose 1 -phosphate and free fatty acids plus glycerol, 
respectively, is shown in scheme 1. A great deal is 
already known about the control of hepatic glycogen 
breakdown [ 1 l] whereas very little is known about 
the control of hepatic glyceride degradation. 
The close and to some extent reciprocal relation- 
ships in liver between glucose and fatty acid meta- 
238 
holism may be understood in the light of the major 
role of these processes in the rapid events of homeo- 
stasis of vital blood fuels, and in the adaptive hepatic 
responses to variations in ingested food. These adapta- 
tions (e.g., to starvation) involving reciprocal changes 
in neogenesis of fatty acids and glucose, may partly 
be viewed in terms of alteration of the fate of mito- 
chondrial pyruvate. It is likely that, in animals ingest- 
ing significant quantities of glucose a major fate of 
plasma lactate is conversion to fatty acids. Such carbon 
cannot re-enter the carbohydrate pool, i.e., the Cori 
‘cycle’ is thereby broken. During relative glucose depri- 
vation, blood lactate is likely to convert predominantly 
to glucose, rather than fatty acid. 
Given the above considerations, it is not surprising 
that some hormones seem to exert their most potent 
rapid effects simultaneously on carbohydrate and 
lipid metabolism in liver. Catabolic effects of this 
type are the subject of this article. 
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3. Short-term catabolic hormonal control of liver 
glycogen metabolism 
Glycogen degradation can be rapidly stimulated 
by hormones. The paradigm for this type of effect is 
that of glucagon, the peptide produced by the A-cells 
of the endocrine pancreas, which enters the blood 
stream in the hepatic portal vein. Glucagon causes 
breakdown of liver glycogen at plasma concentrations 
of lo-” M or greater, as may easily be demonstrated 
by measurements of glucose output in the perfused 
liver [ 12,131. This remains one of the most sensitive 
and reproducible among metabolic effects of hormones 
(on any tissue). 
Another well established catabolic hormone effect 
is that of adrenaline, which can stimulate liver 
glycogen breakdown at plasma concentrations of 
10-s M or greater [ 141. Noradrenaline probably exerts 
a similar effect, over approximately the same con- 
centration range. 
A third hormone which stimulates the degradation 
of liver glycogen is vasopressin, the nonapeptide 
(counting cys-S-S-cys as two amino acids) produced 
by the posterior pituitary gland. In the perfused liver 
of the fed rat [ 14,151 or mouse [16] vasopressin can 
cause glucose release at concentrations of about 
2.5 X lo-” M. 
Fig.1. Concentration-dependence of short-term catabolic 
effects of hormones on liver glycogen metabolism. Livers 
were perfused with bicarbonate-buffered saline containing 
glucose and erythrocytes. Increase in the amount of 
glycogen phosphorylase a activity (A phos. a on ordinate: 
pmol/min/g) was determined 5 min after vasopressin (VP), 
angiotensin II (A II) or adrenaline (Adr); data, with permission, 
are from ref. [ 141. In livers from starved rats, inhibition in 
the rate of net glycogen synthesis during 30 min. perfusion 
(5% max. glyc. synth. on ordinate) was measured in response 
to oxytocin (oxy) or parathyroid hormone (PTH); data, with 
permission, are from refs. [ 181 and [ 191 respectively. 
Angiotensin II can also stimulate glycogen break- 
down, as shown by measurements of glucose output 
in the perfused rat liver [ 141 ; the minimum effective 
concentration is about 3 X lo-” M. 
Clearly a wide range of hormones is capable of 
stimulating glycogen breakdown in the liver (fig.1). 
This susceptibility to degradation is reminiscent of 
the response of adipose tissue triglyceride to a variety 
of hormones. Further hormones which can directly 
stimulate hepatic glycogen breakdown include para- 
thyroid hormone [ 171 and some gut peptides, such 
as enteroglucagon and vasoactive intestinal peptide. 
All of the hormones mentioned above can inhibit 
glycogen synthesis. The minimum effective concentra- 
tion of vasopressin, which inhibits synthesis in the 
perfused rat liver, is about lo-” M, i.e., the liver in 
this situation exhibits a more than 2-fold increase in 
sensitivity to hormone (cf. with the fed state) [ 151. 
In view of this feature, the starved animal was selected 
for a study of the response of net hepatic glycogen 
synthesis to oxytocin and parathyroid hormone. 
Minimum effective inhibitory concentrations were 
respectively, about 2 X lo-* M [18] and 5 X 10m8 M 
[191. 
The concentration-dependences of some of these 
catabolic hormonal effects on glycogen metabolism 
in liver are shown in fig. 1. 
The converse process to glycogen breakdown is Regarding glycogen synthesis, no credible short- 
glycogen synthesis. Net synthesis of glycogen can be term stimulation of this process by any hormone 
followed in the perfused liver, or in hepatocyte acting alone and directly on the liver has yet been 
suspensions, from starved rats. Maximum rates require reported. Insulin has been tested many times for 
glucogenic sources of carbon which form glucose- such an effect, but it appears that in fully aerobic 
phosphates, and also glucose to act as a stimulator conditions, insulin may not produce any rapid effect 
of glycogen synthesis [l] , i.e., glucose directs the on hepatic glycogen metabolism (e.g. [2,20,21] ). 
newly-synthesised hexose-phosphates to glycogen Insulin can however, suppress the actions of glucagon 
([l] for review see ref. [ll]). or adrenaline to stimulate glycogen breakdown [ 131 
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and would presumably de-inhibit (i.e., stimulate) 
glycogen synthesis, in the presence of these hormones. 
The process of gluconeogenesis is closely involved 
with events of glycogen metabolism (scheme 1; 
ref. [l] ). So far, it has appeared that hormones 
which stimulate glycogen breakdown also stimulate 
glucose synthesis from a variety of precursors. Such 
stimulation has been shown for glucagon, adrenaline 
[22,23] and vasopressin [15] in experiments with 
livers from starved animals. Hence the overall effect 
of these hormones has been thought to be the promo- 
tion of glucose release by the liver, from both glycogen 
and glucogenic sources. 
However, there is doubt about this general infer- 
ence, in the case of adrenaline, vasopressin and angio- 
tensin II, which at their lowest effective concentra- 
tions can all rapidly stimulate the amount of phos- 
phorylase a in liver without associated glucose release 
[ 141. These hormones may therefore (in the short- 
term in glycogen-containing livers at least), stimulate 
glycogenolysis to produce hexosephosphates for con- 
sumption within the liver, e.g., via glycolysis. 
4. Short-term catabolic hormonal control of hepatic 
lipid metabolism 
Hepatic glyceride metabolism has some general 
features in common with glycogen metabolism 
(scheme l), although fat in liver (3-8% in normal 
animals, with triglyceride amounting to l-3%) does 
not undergo such wide or rapid fluctuations as 
glycogen in respect of its role as a fuel store. 
The processes of glyceride metabolism may be 
considered in the same order as were those of glycogen 
metabolism. Taking glyceride breakdown (‘lipolysis’) 
first, this process is difficult to measure in liver. Two 
valid measures would be (a) direct, i.e., net changes 
in glycerides with time, (b) changes in a relevant 
lipase activity. (In the case of glycogen, both these 
measures of degradation are easily available.) However, 
given this view, there are few systematic studies of 
hormonal stimulation of lipolysis which may be 
cited. Measurements of content of metabolites such 
as free fatty acids or their thioesters can in no way 
provide an estimate of lipolysis. 
Glucagon can increase the extent of depletion of 
hepatic triglyceride during perfusion of the rat liver 
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[24] ; evidence of stimulation of lipolysis also comes 
from a study of release of 14C-labelled free fatty acid 
from pre-labelled triglyceride during liver perfusion 
[25]. It would be expected that insulin would counter- 
act this effect; indeed insulin alone can suppress tri- 
glyceride degradation in the perfused mouse liver [26]. 
Triglyceride synthesis from blood-borne free fatty 
acids can be stimulated by insulin [27] and probably 
inhibited by glucagon. Triglyceride export by liver, 
in very-low density lipoproteins, can be stimulated 
by insulin [27] and inhibited by glucagon [28] . 
The process of synthesis de novo of fatty acids 
(designated neogenesis of fatty acid in scheme l), 
bears the same relationship to glyceride metabolism 
as does gluconeogenesis to glycogen metabolism 
(scheme 1). Again, we should look for rapid effects 
of catabolic hormones, which might be expected to 
inhibit fatty acid synthesis, as this is conventionally 
regarded as a ‘biosynthesis’ (in contrast to gluconeo- 
genesis). This perhaps arbitrary distinction is unfounded 
in that hepatic liponeogenesis is faster than was hitherto 
believed, as may be shown by measuring 3H incorpora- 
tion from 3Hz0 [4,6]. But sure enough, vasopressin 
[16] adrenaline, and angiotensin II [29] can rapidly 
inhibit fatty acid synthesis, at least in mouse liver 
(table 1). In the case of vasopressin, the concentra- 
tion-dependence of the inhibition of fatty acid synthesis 
is identical to that for stimulation of glycogen break- 
down [16], suggesting that the initial stages of the 
mechanisms of action on these two processes may be 
common. 
Glucagon can also inhibit fatty acid synthesis, but 
there may be a difference between this inhibition, and 
that exerted by other hormones. The inhibitory effect 
of glucagon in the perfused liver is not exerted at con- 
centrations which occur in plasma (i.e. is less potent 
than that on glycogen breakdown: ref. 13), whereas 
there is inhibition in preparations such as slices where 
functional viability is not as good as it is in the per- 
fused liver [30] . The inhibitory action of glucagon 
on fatty acid synthesis may be secondary in time to 
the primary metabolic effects of the hormone on carbo- 
hydrate metabolism. In particular, glucagon depletes 
the liver of glycogen, a favoured source of acetyl units 
for fatty acid synthesis [4]. 
Rapid effects of hormones on cholesterol synthesis 
in liver have not been studied as extensively as in the 
case of fatty acid synthesis. Glucagon can inhibit 
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Table 1 
Inhibition of fatty acid synthesis in mouse liver by hormones 
August 1977 
Hormone 
(M) 
Fatty acid synthesis Acetyl-CoA carboxylase 
(pmol Q-units/g/h) activity (initial 
activity, as % of total) 
None 27 56 
Vasopressin, 3 X 1O‘9 10 47 
Adrenaline, 2 X 10m7 12 31 
Angiotensin 11, 4 X 10m9 8 42 
Livers of fed mice were perfused with saline containing albumin, glucose (15 mM), 
lactate (10 mM) and erythrocytes. After addition of hormones, or in control 
livers, fatty acid synthesis was measured with ‘H,O [ 161 and acetyl-CoA 
carboxylase activity was assayed, before and after 30 min treatment with citrate 
[ 291. Data are taken, with permission, from refs. [ 161 and [ 291, (except for the 
vasopressin effect on acetyl-CoA caiboxylase: unpublished experiments of 
G. Y. Ma and C. D. Gove). All hormone effects are significant (compared to the 
control value; p < O.OS), except that of vasopressin on the enzyme activity 
synthesis of cholesterol in liver [3 l] , whereas adrena- 
line may stimulate synthesis [32] . 
5. Mechanism of rapid catabolic action of hormones 
on hepatic glycogen 
All hormones which can stimulate glycogenolysis 
act by increasing the amount of phosphorylase a in 
liver. This response, demonstrated for glucagon [33] 
adrenaline [ 14,221 angiotensin II [ 14,341 and vaso- 
pressin [7,14,35] must be mediated by alterations in 
the relative activities of phosphokinases and phospha- 
tases which act on phosphorylase. 
The action of glucagon on the liver appears to be 
mediated by the ‘cascade’ of responses initiated by 
the stimulation of the plasma membrane adenyl 
cyclase and followed by activation of cyclic-AMP- 
dependent protein kinase and phosphorylase b 
kinase, so that eventually phosphorylase a concentra- 
tion increases. All the reactions of this cascade have 
been demonstrated to occur in intact-cell preparations 
in vitro, in response to glucagon [33,36,37]. 
There seems little reason to doubt this ‘dogma’ 
(a testimony to the most towering achievement in 
modern biochemical endocrinology, stemming, of 
course, from the work of E. W. Sutherland), in regard 
to glucagon action on the liver. Intriguingly though, 
cyclic-AMP may not be involved in the degradation of 
glycogen caused by the lowest effective concentrations 
of glucagon [38] ; also, cations may be implicated in 
the mechanism of glucagon action, in conjunction with 
cyclic-AMP [39] . 
Apart from glucagon, hormones which can exert 
their short-term catabolic effect on the liver through 
cyclic-AMP include /3-adrenergic agonists [40] and 
perhaps parathyroid hormone [17,41] . Whether this 
involves one cyclase and a series of hormone-binding 
subunits remains to be definitively clarified. 
The other hormones which exert a catabolic effect 
on liver, mentioned above, do not act through cyclic- 
AMP. The existence of rapid catabolic effects in liver, 
not mediated by cyclic-AMP or its dependent protein 
kinase, was first shown for cY-adrenergic agonists [40] 
and has been confirmed [22,23,36,37,42]. Although 
this is in one sense a ‘negative’ result, it is a very 
powerful one, as it suggests that none of the cellular 
effects of a-adrenergic agents are mediated by cyclic- 
AMP. 
Vasopressin also does not increase the cyclic-AMP 
content of liver [43] , and neither do angiotensin II or 
oxytocin (K. Siddle, C. Davies and D. A. Hems: 
unpublished data). The assayable protein kinase 
activity in hepatocyte suspensions is not increased by 
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vasopressin or angiotensin II [34,35] . An alternative 
candidate for mediation of the actions of these 
hormones on liver would be cyclic-GMP. However 
the content of this nucleotide in perfused liver does 
not alter in response to vasopressin, oxytocin or 
angiotensin II (K. Siddle, C. Davies and D. A. Hems: 
unpublished data). Cyclic-GMP has been shown to 
exert a catabolic action on liver glycogen [44] SO 
that hypotheses which propose opposite effects (‘Yin 
and Yang’) of cyclic-GMP and cyclic-AMP in the 
short-term control of liver metabolism do not appear 
to be tenable, on the evidence so far. The role of 
cyclic-GMP in liver remains problematical. 
Thus there is a group of hormones able to exert 
short-term catabolic effects on liver, which are not 
mediated by purine nucleotide cyclic monophosphates. 
This group of hormones comprises a-adrenergic 
agonists, vasopressin, oxytocin and angiotensin II 
(so far). There must be different receptors for cate- 
cholamines (&-receptors), neurohypopyseal peptides, 
and angiotensin II, as their structures are different. 
These receptors still have to be isolated and charac- 
terized. 
Several of the above hormones are potent vaso- 
constrictor agents. In the rat liver, angiotensin II 
and adrenaline exert a direct potent constrictor action 
on the portal vasculature, whereas vasopressin does 
not [ 141. These vasoconstrictor effects severely 
hamper the interpretation of catabolic effects obtained 
in vivo by hormone administration, since ischaemia 
and consequent hypoxia would themselves produce 
catabolic effects. However, it is established that the 
hormones under discussion here do not act solely on 
liver vasculature. In particular, they all can cause 
glycogen breakdown in hepatocyte suspensions, where 
there is no question of an ischaemic origin of the 
response [45-471. 
How then may these hormones bring about the 
increase in amount of phosphorylase a in the liver? 
Inorganic ions, and Ca’+in particular, are often 
implicated in the actions of extracellular agents on 
cells, so it is a reasonable hypothesis that Ca2+is 
implicated in the actions of agents that do not affect 
purine nucleotide cyclic monophosphates. This seems 
to be the case for vasopressin action on hepatic glyco- 
gen breakdown, since extracellular Ca2+ is critical for 
this effect, to an extent that is more marked than for 
the actions of adrenaline and glucagon [45]. The same 
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is true of angiotensin II action on hepatic glycogen 
breakdown [46,47]. 
As might be expected from the above observations, 
Ca2+uptake by cells is increased by vasopressin and 
angiotensin II [46] . Ca2+ could be involved in the 
eventual increase in glycogen phosphorylase a, e.g., 
through activation of phosphorylase b kinase, which 
is very sensitive to Ca2+ [37,48,49]. However, the 
observation that extracellular Ca2+ is crucially impli- 
cated in hormone action is a far cry from solving the 
mechanism, especially in view of the fact that glucagon 
can also stimulate Ca2+ entry into liver, i.e., this 
response is not specific to hormones which do not 
affect the adenyl cyclase [46]. Thus the question of 
the mechanisms of action of this group of hormones 
which do not act via cyclic purine nucleotide mono- 
phosphates in liver is wide open. 
6. Functional significance of catabolic hormone effects 
on the liver 
The question arises of the importance in the animal 
of the above-described catabolic effects on the liver. 
A common feature of these hormones is that they 
all increase in concentration in blood in stress, adap- 
tive or pathological states. The role of glucagon in 
stress states has been widely documented and reviewed. 
Although glucagon in the hepatic portal vein undoubt- 
edly can cause glycogenolysis in liver, over the ‘normal 
range’ of concentrations of hormone in plasma, 
glucagon may not be a major hormone in mature 
mammals. There are no common diseases involving 
excess or lack of glucagon. Administration of anti- 
bodies to glucagon produces no major upset [SO]. 
Diabetes caused by pancreatectomy closely resembles 
that due to selective p-cell damage, showing that 
pancreatic glucagon action is not crucial in any of 
the features of diabetes (as yet reported), although 
there may be a contribution when raised plasma 
glucagon levels are present (for review, see ref. [5 I] ). 
Among the other hormones described here, 
adrenaline, vasopressin and angiotensin II are all 
potent vasoconstrictor agents in the intact animal. 
As would be expected, they have a role in the main- 
tenance of blood pressure, especially in haemorrhagic 
states [52]. The circulating concentrations of adren- 
aline, vasopressin and angiotensin II also increase in 
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other conditions (e.g., starvation, hypoglycaemia, 
Na’ depletion) to levels which will affect the liver 
(see discussion in ref. [ 141). 
A variety of stress states are associated with hyper- 
glycaemia [53] perhaps to maintain the glucose con- 
tent and osmolarity of the blood. It is probable that 
hormones such as those being discussed here have a 
role in producing this hyperglycaemia. 
In the case of adrenaline, the view expressed here 
that circulating hormone can act directly on the liver 
to stimulate glycogenolysis merely resurrects an old 
idea, viz. that the antagonistic actions of insulin and 
adrenaline on liver glycogen are relevant in glucose 
homeostasis. 
At their lowest effective concentrations, vaso- 
pressin, angiotensin II and adrenaline can stimulate 
glycogen degradation without associated glucose 
release [ 141. Glucose-phosphates derived from 
glycogen may undergo further degradation by, e.g., 
glycolysis, in such conditions. This would make sense 
in hypoxic liver during shock. 
If the hepatic catabolic effects of oxytocin and 
parathyroid hormone are relevant in vlvo in any 
particular state of the animal, this state has not yet 
been identified. 
Fatty acid synthesis in liver would be expected to 
decrease during stress, shock or adaptive states, as 
acetyl residues require to be conserved for oxidation. 
As one main precursor of fatty acid synthesised in 
liver is glycogen [4] such inhibition would free 
glycogen-derived glucose-phosphates for consump- 
tion in other pathways. The catabolic effect of 
hormones on fatty acid synthesis may be understood 
in this light. 
In summary then, the range of catabolic hormone 
effects on liver contributes to the multiple rapid 
alterations required in states of stress, or adaptation. 
Many such hormone effects (on all tissues) then come 
into play, but recede in unstressed conditions. There 
does not appear to be such a wide battery of ‘non- 
stress’ hormones; thus ‘non-stress’ is merely a state 
where catabolic hormone effects are minimal. 
7. Catabolic effects of hormones on liver in diabetes 
and obesity 
The hormone effects on liver. which are the sub- 
ject of this article, have relevance to the metabolic 
events in diabetes and obesity. Thus diabetes due to 
insulin deficiency is associated with hyperglycaemia, 
a relative depletion of liver glycogen (due partly to an 
intrinsic decline in hepatic capacity to synthesize 
glycogen: ref. [20] ), an increase in capacity for 
gluconeogenesis, and a decline in hepatic fatty acid 
synthesis. 
All these consequences would follow if the cata- 
bolic hormones under consideration here were to 
exert catabolic actions on liver in diabetes. When 
diabetes is of the severe ketotic type, there is hyper- 
osmolarity associated with an increase in plasma 
renin activity [54] and presumably therefore of 
angiotensin II concentration. This increase could con- 
tribute to the hyperglycaemia and decline in hepatic 
fatty acid synthesis, through direct hepatic action. 
In such hyperosmolar diabetes, plasma vasopressin 
would also be likely to increase, and exert catabolic 
actions on liver; this possibility has not been system- 
atically studied. Plasma adrenaline concentration 
can also increase in diabetes [55] , so that this hormone 
may be a partial cause of hyperglycaemia in diabetes 
in some circumstances. 
Obesity is a state in which intrinsic alterations in 
hormonal and metabolic status lead to a tendency to 
increase fat deposition in tissues (including blood 
vessels). Much information about this serious condition 
has come from the study of genetically obese rodents, 
in which the most significant alteration is perhaps 
their increased concentration of plasma insulin. In 
general, the alterations in lipid metabolism in obese 
rodents are less susceptible to reversal by food depri- 
vation than are those in carbohydrate metabolism. 
This is true for example of the increases in hepatic 
lipogenesis [6], plasma turnover of triglyceride, free 
fatty acid and glycerol [56,57] and utilisation of 
plasma triglyceride by tissues [58] which are observed 
in genetically obese mice. 
It is likely that some of these metabolic alterations 
in obesity are due to excessive influence of circulating 
insulin [59]. However, this explanation may leave 
several questions unanswered, such as why is insulin 
action not counteracted in tissues? This raises the 
general issue of hormonal responses in tissues of obese 
.animals. One clue has emerged from studies with 
hormones which exert catabolic actions on liver. .The 
liver in genetically obese mice is resistant to the inhi- 
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bition of lipogenesis which vasopressin causes in the 
liver of normal mice [60]. However, the liver is not 
resistant to the action of vasopressin to stimulate 
glycogen breakdown, or to the action of glucagon on 
glycogen breakdown. 
It may be warranted to regard this lesion in vaso- 
pressin action on liver as reflecting very closely the 
inborn lesion in obese mice, as it is intractable to 
starvation, and as an impairment in inhibition of fatty 
acid synthesis would be expected to be associated 
with obesity. Therefore it appears that genetically 
obese mice, homozygous for the ob gene, exhibit a 
selective impairment in the cellular responses to 
extracellular effecters which are not mediated by 
purine nucleotide cyclic monophosphates. Such a 
defect in cell response mechanisms could cause altera- 
tions in the function of many tissues, such as are 
indeed exhibited by obese rodents. Extrapolating to 
human obesity, this inference would suggest hat atten- 
tion be directed to the rapid response mechanisms of 
cells, (to catabolic agents, neurotransmitters, etc.) 
which do not operate through purine nucleotide 
cyclic monophosphates, in order to gain insight into 
this condition, and to bring about therapeutic 
advances. 
8. Conclusion 
The above account has brought out the existence 
of a range of hormones which can exert catabolic 
effects on liver glycogen and fat metabolism. The 
hepatic effects of these hormones are relevant in the 
intact animal. Some of these hormones do not exert 
their actions through cyclic-monophosphates of 
adenosine or guanosine. Resolution of the mechanisms 
underlying their effects on liver cells should provide 
insight into regulatory responses in cell membranes, 
and perhaps into endocrine disorders. 
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